Last reviewed · How we verify
ALXN1840 Enteric-coated Tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ALXN1840 Enteric-coated Tablet (ALXN1840 Enteric-coated Tablet) — Alexion Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ALXN1840 Enteric-coated Tablet TARGET | ALXN1840 Enteric-coated Tablet | Alexion Pharmaceuticals, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ALXN1840 Enteric-coated Tablet CI watch — RSS
- ALXN1840 Enteric-coated Tablet CI watch — Atom
- ALXN1840 Enteric-coated Tablet CI watch — JSON
- ALXN1840 Enteric-coated Tablet alone — RSS
Cite this brief
Drug Landscape (2026). ALXN1840 Enteric-coated Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/alxn1840-enteric-coated-tablet. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab